# Progress Note 07 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Irène Joliot-Curie (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-RB003-SYN
- Date: 2026-10-30
- Fictional facility: St. Posthumous Health Center
- Fictional author: Solène Marchand-Ellis, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Count recovery, response assessment, cycle 2, transplant planning, and her dose records. **S**

## History of present illness

Mrs. Joliot-Curie returns on day 33, eleven days after venetoclax was stopped. She feels stronger, walks for half an hour, and has begun reading papers again. She has had no fever or bleeding. Her posaconazole trough level, drawn three days ago, was in the target range. The transplant center reports that the unrelated donor search has found two fully matched donors. Her employer's radiation safety office has acknowledged her request and is assembling her dose records, including the bioassay from the laboratory accident. **S**

| Element | Detail |
|---|---|
| Cycle | Day 33 of cycle 1; venetoclax stopped on day 22 |
| Symptoms | Stronger; no fever or bleeding |
| Transplant | Two fully matched unrelated donors identified |
| Dose records | Request acknowledged; records being assembled |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy improving; no fever or night sweats |
| Respiratory | Positive | Breathless on stairs, as before |
| Gastrointestinal | Negative | Eating well; bowels regular |
| Integumentary | Negative | No bruises |
| Psychiatric | Negative | Mood steady; PHQ-9 6 |

5 systems reviewed. **S**

## Current medications

- Azacitidine 115 mg (75 mg/m2) under the skin once daily on days 1 to 7 of each 28-day cycle **S**
- Posaconazole 100 mg delayed-release tablet, three tablets (300 mg) twice on day 1, then three tablets once daily, as antifungal prophylaxis while neutropenic **S**
- Acyclovir 400 mg oral tablet, one tablet twice daily as herpes simplex and zoster prophylaxis **S**
- Ondansetron 4 mg orally disintegrating tablet, one tablet every 8 hours as needed for nausea **S**
- Polyethylene glycol 3350, 17 g powder in a glass of water once daily **S**
- Venetoclax 10 mg oral tablet, cycle 2: two tablets daily with the 50 mg tablet (70 mg a day, the dose with posaconazole) on days 1 to 21 **S**
- Venetoclax 50 mg oral tablet, cycle 2: one tablet daily with two 10 mg tablets (70 mg a day) on days 1 to 21 **S**

## Allergies

- No known allergy **S**

## Objective

BP 118/72 mmHg; pulse 84 bpm; respirations 16/min; temperature 36.8 °C; oxygen saturation 98% on room air; weight 53.6 kg; BMI 20.2 kg/m². All vital signs are synthetic.

White cell count: 2.2 10*3/uL (low); Absolute neutrophil count: 0.9 10*3/uL (low); Hemoglobin: 9.6 g/dL (low); Platelets: 88 10*3/uL (low); Blood blasts (smear): 0%; Sodium: 139 mmol/L; Potassium: 4.2 mmol/L; Creatinine: 0.81 mg/dL; eGFR: 84 mL/min/1.73 m²; ALT: 28 U/L; ECOG performance status: 1; PHQ-9: 6. All results are synthetic.

## Change since baseline

- White cell count: 2.1 10*3/uL (low) at baseline, 2.2 10*3/uL (low) at this visit **S**
- Absolute neutrophil count: 0.6 10*3/uL (low) at baseline, 0.9 10*3/uL (low) at this visit **S**
- Hemoglobin: 8.4 g/dL (low) at baseline, 9.6 g/dL (low) at this visit **S**
- Platelets: 38 10*3/uL (low) at baseline, 88 10*3/uL (low) at this visit **S**
- Blood blasts (smear): 12% (high) at baseline, 0% at this visit **S**
- Sodium: 139 mmol/L at baseline, 139 mmol/L at this visit **S**
- Potassium: 4 mmol/L at baseline, 4.2 mmol/L at this visit **S**
- Creatinine: 0.78 mg/dL at baseline, 0.81 mg/dL at this visit **S**
- eGFR: 88 mL/min/1.73 m² at baseline, 84 mL/min/1.73 m² at this visit **S**
- ALT: 22 U/L at baseline, 28 U/L at this visit **S**
- ECOG performance status: 1 at baseline, 1 at this visit **S**
- PHQ-9: 5 at baseline, 6 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Brighter; weight 53.6 kg; ECOG 1 |
| Mouth | No ulcers or thrush |
| Respiratory | Fine crackles at the right apex, unchanged |
| Skin | No bruises or petechiae |
| Abdomen | No enlarged liver or spleen |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Acute myeloid leukemia after cycle 1** (C92.00). Neutrophils 0.9 and platelets 88 x10^3/uL with no circulating blasts, after a day-22 marrow with 3 percent blasts: complete remission with partial hematologic recovery (ELN 2022), with measurable residual disease still detectable. This is a good first response, but TP53-mutated leukemia often relapses, so the plan is to continue azacitidine with venetoclax and move to a reduced-intensity allogeneic transplant from a matched unrelated donor after two to three more cycles if remission holds. We discussed this plainly, with the numbers she asked for. **S**
   - Cycle 2 from today: azacitidine days 1 to 7 and venetoclax 70 mg on days 1 to 21.
   - Stop levofloxacin now that neutrophils are above 0.5; continue posaconazole and acyclovir.
   - Measurable residual disease marrow after cycle 2.
   - Transplant center visit to plan timing and conditioning.
2. **Occupational exposure to ionizing radiation** (Z57.1). Records requested and acknowledged; they will be reviewed with her and kept in the chart. **S**
   - Review the dose records when received.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Blood count with differential and smear | At diagnosis; two to three times a week during induction; before each cycle | Completed today | White cells 2.2, neutrophils 0.9, hemoglobin 9.6 g/dL, platelets 88 x10^3/uL; no blasts: ELN 2022 complete remission with partial hematologic recovery |
| Laboratory | Bone marrow: morphology, flow cytometry, cytogenetics, molecular panel | At diagnosis; day 21 to 28 of cycle 1; then as response and transplant planning require | Due | Measurable residual disease marrow after cycle 2 |
| Laboratory | Chemistry: electrolytes, creatinine, calcium, phosphate, uric acid, LDH, liver tests | At diagnosis; during venetoclax ramp-up for tumor lysis; then weekly in cycle 1 and before each cycle | Completed today | Sodium 139, potassium 4.2 mmol/L; creatinine 0.81 mg/dL, eGFR 84; ALT 28 U/L |
| Medication safety | Azole safety: posaconazole interactions (venetoclax dose), liver tests, QTc, trough level | At start; liver tests weekly; trough level after about a week of dosing; QTc with any added QT-prolonging drug | Completed today | Trough level in the target range three days ago; liver tests normal; venetoclax kept at 70 mg |
| Survey | Performance status | Before each cycle | Completed today | ECOG 1, from 2 at the start of treatment |
| Medication safety | Transfusion support: thresholds, irradiated and leukoreduced products | At each blood count | Completed today | No transfusion needed since day 11 |
| Self-management | Infection prophylaxis and the fever plan | Throughout neutropenia | Completed today | Levofloxacin stopped; posaconazole and acyclovir continue through cycle 2; fever plan unchanged |
| Referral | HLA typing and allogeneic transplant evaluation | During remission | Completed today | Two matched unrelated donors found; reduced-intensity transplant planned after two to three more cycles |
| Referral | Specialist palliative care: symptoms, prognosis, goals and values | At every visit | Completed today | Palliative care continues alongside treatment; goals recorded at the preventive visit |
| Survey | Distress, depression and anxiety screening | At each phase of treatment | Completed today | PHQ-9 6, mild |
| Self-management | Occupational exposure history and dose records | Until the records are received | Due | Request acknowledged; records being assembled |

## Goal progress

- Diagnosis, classification and a treatment decision within two weeks of the first visit. Outcome by 2026-09-28: Marrow two days after the first visit; genetics back and treatment started on day 14. **S**
- Complete cycle 1 without tumor lysis, invasive fungal infection, or bleeding. Outcome by 2026-10-30: No tumor lysis; no fever or fungal infection; no bleeding beyond bruising; one outpatient visit for nausea. **S**
- Remission on the response assessment after cycle 1 (ELN 2022 complete remission, or complete remission with partial hematologic recovery). Outcome by 2026-10-30: Day-22 marrow blasts 3%; at day 33 neutrophils 0.9 and platelets 88: complete remission with partial hematologic recovery, measurable residual disease positive. **S**
- Her own goals and values recorded and her symptoms controlled with the palliative care team from the first cycle. Outcome by 2026-09-28: Seen by the palliative care team on day 1; goals recorded; symptoms reviewed at every visit. **S**
- Her occupational dose records obtained and the exposure history documented. Outcome by 2026-10-30: Records requested in writing from the employer's radiation safety office; history documented. **S**

## Medication changes

- Stopped: Levofloxacin 500 mg oral tablet, one tablet daily while the neutrophil count is below 0.5 **S**
- Started: Venetoclax 10 mg oral tablet, cycle 2: two tablets daily with the 50 mg tablet (70 mg a day, the dose with posaconazole) on days 1 to 21 **S**
- Started: Venetoclax 50 mg oral tablet, cycle 2: one tablet daily with two 10 mg tablets (70 mg a day) on days 1 to 21 **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia, Version 5.2026 (2026), National Comprehensive Cancer Network
- Döhner H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 2022 (PMID 35797463) (2022), European LeukemiaNet (Blood)
- DiNardo CD, et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia (VIALE-A). N Engl J Med 2020 (PMID 32786187) (2020), New England Journal of Medicine
- NCCN Clinical Practice Guidelines in Oncology: Prevention and Treatment of Cancer-Related Infections (2026), National Comprehensive Cancer Network
- Taplitz RA, et al. Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: ASCO and IDSA Clinical Practice Guideline Update (PMID 29461916) (2018), American Society of Clinical Oncology and Infectious Diseases Society of America (Journal of Clinical Oncology)
- Sanders JJ, et al. Palliative Care for Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2024 (PMID 38748941) (2024), American Society of Clinical Oncology
- Carson JL, et al. Red Blood Cell Transfusion: 2023 AABB International Guidelines. JAMA 2023 (PMID 37824153) (2023), Association for the Advancement of Blood and Biotherapies (JAMA)
- Kaufman RM, et al. Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med 2015 (PMID 25383671) (2015), AABB (Annals of Internal Medicine)
- 10 CFR 19.13, Notifications and reports to individuals (radiation exposure reports on request) (2026), U.S. Nuclear Regulatory Commission (Electronic Code of Federal Regulations)
- 29 CFR 1910.1096, Ionizing radiation (records of exposure and disclosure to employees) (2026), Occupational Safety and Health Administration
- Depression and Suicide Risk in Adults: Screening (2023), U.S. Preventive Services Task Force

## Follow-up

- Cycle 2 as planned, with twice-weekly blood counts. Marrow after cycle 2. Transplant center visit in two weeks. Palliative care at each visit. Emergency department at once for a temperature of 38.0 °C or more. **S**

